Back to search results

Mobile App Study for IgAN Disease Burden and Treatment

This observational study uses a mobile app to understand how Immunoglobulin A Nephropathy (IgAN) affects patients and their caregivers in the US. Researchers want to learn about your symptoms, how they change over time, and how treatments like iptacopan or atrasentan impact your quality of life. You can join if you have IgAN, are 18 or older, or are an adult caregiver to an IgAN patient (adult or child). The study will track your symptoms and quality of life monthly for up to 6 months. This helps researchers understand the full experience of living with IgAN. The study is currently recruiting 300 participants.

Study design
This is an observational study, meaning researchers will collect information without giving you any new treatments. It plans to enroll 300 participants.
What's involved
You will use a mobile app to track your symptoms and health for an initial 6 months. This includes a baseline survey, monthly check-ins, and an end-of-study survey.
Compensation
Not stated in the trial record.
Follow-up
After the initial 6-month data collection, you can continue using the app for personal tracking, and with your consent, this data may be reviewed for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06952426

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Recruiting
Not specifiedAges 18+Observational
Novartis Pharmaceuticals
~300 participants
Updated 2025-06-17 on ClinicalTrials.gov
What's tested:No interventionOther treatmentIptacopanAtrasentan

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with IgAN specific symptoms
Measured over monthly up to month 6
+2 more outcomes measured

Conditions

Immunoglobulin A Nephropathy

Explore related trials

IgA Nephropathy

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

Novartis Pharmaceuticals
[email protected]
+41613241111
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of IgAN, regardless of symptom or treatment history
Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
US-based with a proficient understanding of and ability to read the English language

What this trial measures

  • Number of participants with IgAN specific symptomsmonthly up to month 6

    To assess and gain a comprehensive understanding of the patient-reported burden of Immunoglobulin A nephropathy (IgAN) using home-reported outcome (HRO) symptom tracking data. Patients will select from a list of suggested symptoms. The 10 symptoms most frequently reported will be presented and analyzed.

  • Average self-reported severity of each of these top 10 symptomsmonthly up to month 6

    To assess and gain a comprehensive understanding of the patient-reported burden of IgAN using HRO symptom tracking data.

  • Variability in self-reported severity of each of these top 10 symptomsmonthly up to month 6

    To assess and gain a comprehensive understanding of the patient-reported burden of IgAN using HRO symptom tracking data.